Exploring the Mechanism of Action of Honeybran‐Fried Cimicifuga Rhizoma in the Treatment of IBS‐D Based on Metabolomics and Network Pharmacology
Biomedical Chromatography · 2025
DOI: 10.1002/bmc.70026 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomedical Chromatography, 2025. Verfasst von Jing Zhu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Research Center of Chinese Medicine Resource and National Medicine, Jiangxi University of Chinese Medicine, Nanchang, China. Hauptthemen laut MEDLINE: Metabolomics, Drugs, Chinese Herbal, Cimicifuga, Metabolome. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben. Gefördert von: Jiangxi Provincial Natural Science Foundation, Jiangxi University of Traditional Chinese Medicine Traditional Chinese Medicine Concoctions Technology Inheritance Innovation Team Construction Project, National Key Research and Development Program of China.
Abstract (Originalsprache)
Honeybran‐fried Cimicifuga Rhizoma (HBCR) is often used to treat prolonged diarrhea and prolapse of the anus, uterine prolapse, and gastric ptosis caused by spleen qi deficiency and the inability to elevate qi, and thus the lowering of middle qi. Rats were divided randomly into four groups. Fecal samples of rats in each group were subjected to metabolomics analysis. We identified the chemical components of HBCR using liquid chromatography–tandem mass spectrometry. We predicted the potential active components and key targets of HBCR using network pharmacology to construct a “drug–potential active ingredient–target–disease” network. The key targets screened by network pharmacology and differential metabolites screened by metabolomics analysis were subjected to combined pathway analysis. Pharmacodynamic indices showed that HBCR had a good therapeutic effect upon IBS‐D. Metabolomics analysis revealed 26 differential metabolites in the treatment of IBS‐D by HBCR. A total of 69 chemical components were identified, and 32 potential active components and 296 key targets were screened. Combination of metabolomics analysis and network pharmacology for joint pathway analysis revealed that the therapeutic effect of HBCR may be affected by the metabolism of linoleic acid, retinol, arachidonic acid, and tryptophan. HBCR had significant therapeutic effects in rats with IBS‐D.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Research Center of Chinese Medicine Resource and National Medicine, Jiangxi University of Chinese Medicine, Nanchang, China.
- Pharmacy College, Jiangxi University of Chinese Medicine, Nanchang, China.
- School of Pharmacy, Nanchang Medical College, Nanchang, China.
ORCID-Profile: Yuxuan Zou
Förderung
- Jiangxi Provincial Natural Science Foundation
- Jiangxi University of Traditional Chinese Medicine Traditional Chinese Medicine Concoctions Technology Inheritance Innovation Team Construction Project
- National Key Research and Development Program of China
- Jiangxi Provincial Academic and Technical Leaders of Major Disciplines Young Talents Training Program
- Jiangxi Province 'Double Thousand Talents' High-end Talent Program for Youth in Science and Technology Innovation
- Natural Science Foundation of Jiangxi Province
Zitieren
APA
Zhu, J., Zou, Y., Wu, Y., Deng, X., Huang, Y., Yuan, E., & Chen, Q. (2025). Exploring the Mechanism of Action of Honeybran‐Fried Cimicifuga Rhizoma in the Treatment of IBS‐D Based on Metabolomics and Network Pharmacology. Biomedical Chromatography. https://doi.org/10.1002/bmc.70026
Vancouver
Zhu J, Zou Y, Wu Y, Deng X, Huang Y, Yuan E, et al. Exploring the Mechanism of Action of Honeybran‐Fried Cimicifuga Rhizoma in the Treatment of IBS‐D Based on Metabolomics and Network Pharmacology. Biomedical Chromatography. 2025. doi:10.1002/bmc.70026
BibTeX
@article{Zhu2025,
author = {Zhu, Jing and Zou, Yuxuan and Wu, Yigeng and Deng, Xiaoxia and Huang, Yiming and Yuan, En and Chen, Qi},
title = {Exploring the Mechanism of Action of Honeybran‐Fried Cimicifuga Rhizoma in the Treatment of IBS‐D Based on Metabolomics and Network Pharmacology},
journal = {Biomedical Chromatography},
year = {2025},
doi = {10.1002/bmc.70026}
}
EUVIMED